Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

16.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Myriad Genetics Inc

< Previous 1 2 Next >
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Issues 2022 Environmental, Social and Governance Report
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
Myriad to also host Investor Day in South San Francisco in September 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
New collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancer 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Host Investor Day on September 19, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
From Myriad Genetics, Inc.
Via GlobeNewswire
Intermountain Health and Myriad Genetics Participate in ComboMATCH
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385... 
Via PRUnderground
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
ComboMATCH study uses genetic testing to match advanced cancer patients with targeted treatments 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
Myriad Genetics Earns 2023 Great Place to Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in BofA Securities Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms 
From Myriad Genetics, Inc.
Via GlobeNewswire
Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385... 
Via PRUnderground
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program 
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.